sellWeak cluster of 3
Christopher Yea sold $67k of KALV
CHIEF DEVELOPMENT OFFICER at KalVista Pharmaceuticals, Inc.. 7,192 shares at an average of $9.26, traded Nov 18, 2024, filed Nov 19, 2024.
Warning score
23Value
$67k
7,192 shares
Holdings after
89,980
-7% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +15RoleOfficer
- +8Trade size$67k at market
- 0Share of holdings soldSold 7.4% of holdings
- +15Cluster3 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001415889-24-027273, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 17, 2024 | MOption exercise Common Stock | +11,496 | - | - | 97,172 | Nov 19, 2024 |
| Nov 18, 2024 | SOpen-market sale Common Stock | -7,192 | $9.26 | $67k | 89,980 | Nov 19, 2024 |
| Nov 17, 2024 | MOption exercise Restricted Stock Unitderivative | -1,774 | $0.00 | $0 | 10,643 | Nov 19, 2024 |
| Nov 17, 2024 | MOption exercise Restricted Stock Unitderivative | -2,431 | $0.00 | $0 | 9,722 | Nov 19, 2024 |
| Nov 17, 2024 | MOption exercise Performance Stock Unitsderivative | -7,291 | $0.00 | $0 | 0 | Nov 19, 2024 |
Related signals
Other insiders at KalVista Pharmaceuticals, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 44Moderate | KalVista Pharmaceuticals, Inc. | Christopher Yea CHIEF DEVELOPMENT OFFICER | $905k 33,800 shares | -13% | |
| 22Weak | KalVista Pharmaceuticals, Inc. | Paul K. Audhya CHIEF MEDICAL OFFICER | $60k 2,239 shares | -1% | |
| 22Weak | KalVista Pharmaceuticals, Inc. | Christopher Yea CHIEF DEVELOPMENT OFFICER | $53k 1,966 shares | -1% | |
| 21Weak | KalVista Pharmaceuticals, Inc. | Nicole Sweeny Chief Commercial Officer | $40k 1,489 shares | -2% | |
| 23Weak | KalVista Pharmaceuticals, Inc. | Paul K. Audhya CHIEF MEDICAL OFFICER | $72k 2,685 shares | -2% | |
| 39Weak | KalVista Pharmaceuticals, Inc. | Benjamin L Palleiko CHIEF EXECUTIVE OFFICER | $293k 10,926 shares | -2% | |
| 23Weak | KalVista Pharmaceuticals, Inc. | Christopher Yea CHIEF DEVELOPMENT OFFICER | $63k 2,358 shares | -1% | |
| 28Weak | KalVista Pharmaceuticals, Inc. | Brian Piekos Chief Financial Officer | $40k 1,489 shares | -6% | |
| 22Weak | KalVista Pharmaceuticals, Inc. | Nicole Sweeny Chief Commercial Officer | $50k 1,861 shares | -3% | |
| 20Weak | KalVista Pharmaceuticals, Inc. | Paul K. Audhya CHIEF MEDICAL OFFICER | $28k 1,032 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.